JP2020535235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535235A5 JP2020535235A5 JP2020539678A JP2020539678A JP2020535235A5 JP 2020535235 A5 JP2020535235 A5 JP 2020535235A5 JP 2020539678 A JP2020539678 A JP 2020539678A JP 2020539678 A JP2020539678 A JP 2020539678A JP 2020535235 A5 JP2020535235 A5 JP 2020535235A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- composition
- composition according
- subject
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 34
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 21
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 21
- 229920000858 Cyclodextrin Polymers 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 12
- 239000012190 activator Substances 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 7
- 229940114079 arachidonic acid Drugs 0.000 claims description 7
- 235000021342 arachidonic acid Nutrition 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- -1 2-hydroxypropyl Chemical group 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 4
- 108010005714 Interferon beta-1b Proteins 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 230000002440 hepatic effect Effects 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 229960004461 interferon beta-1a Drugs 0.000 claims description 4
- 229960003161 interferon beta-1b Drugs 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 230000000626 neurodegenerative effect Effects 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 230000009858 acid secretion Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 229940022663 acetate Drugs 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 2
- 229960004419 dimethyl fumarate Drugs 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 210000003712 lysosome Anatomy 0.000 claims description 2
- 230000001868 lysosomic effect Effects 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 229960001291 peginterferon beta-1a Drugs 0.000 claims description 2
- 108010027737 peginterferon beta-1a Proteins 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims description 2
- 229960000331 teriflunomide Drugs 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000002132 lysosomal effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000003828 downregulation Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 41
- 208000033868 Lysosomal disease Diseases 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 2
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- 101150018624 ARF6 gene Proteins 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101100379471 Drosophila melanogaster Arf51F gene Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565053P | 2017-09-28 | 2017-09-28 | |
| US62/565,053 | 2017-09-28 | ||
| US201762573658P | 2017-10-17 | 2017-10-17 | |
| US62/573,658 | 2017-10-17 | ||
| US201762586826P | 2017-11-15 | 2017-11-15 | |
| US62/586,826 | 2017-11-15 | ||
| US201862643694P | 2018-03-15 | 2018-03-15 | |
| US62/643,694 | 2018-03-15 | ||
| US201862679912P | 2018-06-03 | 2018-06-03 | |
| US62/679,912 | 2018-06-03 | ||
| PCT/US2018/051604 WO2019067269A2 (en) | 2017-09-28 | 2018-09-18 | USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DISRUPTION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535235A JP2020535235A (ja) | 2020-12-03 |
| JP2020535235A5 true JP2020535235A5 (https=) | 2021-11-04 |
Family
ID=65903379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539678A Pending JP2020535235A (ja) | 2017-09-28 | 2018-09-18 | リン脂質の調節異常が関与する疾患および障害におけるシクロデキストリンの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11471478B2 (https=) |
| EP (1) | EP3687549A4 (https=) |
| JP (1) | JP2020535235A (https=) |
| KR (1) | KR20200107927A (https=) |
| AU (1) | AU2018341235A1 (https=) |
| CA (1) | CA3076821A1 (https=) |
| WO (1) | WO2019067269A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200107927A (ko) | 2017-09-28 | 2020-09-16 | 아스데라 엘엘씨 | 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도 |
| LU100797B1 (en) * | 2018-05-15 | 2019-11-15 | Univ Luxembourg | 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition |
| CN113490691A (zh) | 2019-01-03 | 2021-10-08 | 劣势者药物有限公司 | 环糊精二聚体、其组合物及其用途 |
| BE1027425B1 (fr) | 2019-07-01 | 2021-02-08 | Aquilon Pharmaceuticals | Composition inhalable comprenant de la cyclodextrine a utiliser dans le traitement d’inflammations nasales |
| US11446325B2 (en) | 2020-09-30 | 2022-09-20 | Cyclolab Cyclodextrin Research And Development Laboratory Ltd. | Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases |
| US12285440B2 (en) * | 2021-03-14 | 2025-04-29 | Massachusetts Institute Of Technology | APOE4 impairs myelination via altered cholesterol biosynthesis and transport in oligodendroglia |
| CN115245567B (zh) * | 2021-12-11 | 2023-06-06 | 中国药科大学 | Fgl1抑制剂在制备防治心肌缺血损伤的药物中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5813541A (ja) * | 1981-07-16 | 1983-01-26 | Kureha Chem Ind Co Ltd | エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物 |
| PL220776B1 (pl) | 2002-08-19 | 2016-01-29 | Soho Flordis Internat Pty Ltd | Zastosowanie α-cyklodekstryny do wytwarzania leku do zmniejszania biegunki |
| WO2005011710A1 (en) | 2003-07-28 | 2005-02-10 | The Board Of Trustees Of The University Of Illinois | Per-6-aminosubstituted-deoxy-cyclodextrins to treat alzheimer’s diseases |
| MY141763A (en) * | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| US9034846B2 (en) | 2004-10-10 | 2015-05-19 | Universite De Liege | Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases |
| ATE542527T1 (de) * | 2005-05-13 | 2012-02-15 | Topotarget Uk Ltd | Pharmazeutische formulierungen von hdac-hemmern |
| US7664616B2 (en) | 2006-02-16 | 2010-02-16 | Rockefeller University | Statistical methods for hierarchical multivariate ordinal data which are used for data base driven decision support |
| WO2008067027A2 (en) | 2006-10-20 | 2008-06-05 | Icos Corporation | Compositions of chkl inhibitors and cyclodextrin |
| WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| EP2114374A4 (en) * | 2006-12-27 | 2011-03-23 | Wockhardt Research Center | PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE |
| GB0808479D0 (en) * | 2008-05-09 | 2008-06-18 | Uni I Oslo | Topical compositions |
| FR2935611B1 (fr) | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| CN101704761B (zh) | 2009-10-23 | 2012-09-05 | 宁波斯迈克制药有限公司 | 甲灭酸的合成方法 |
| CN103841961A (zh) | 2011-07-28 | 2014-06-04 | 雪松-西奈医学中心 | 在两亲性间隔基或两亲性聚合物上包含治疗剂的抗氧化剂、神经保护和抗肿瘤纳米颗粒 |
| EP2586436A1 (en) | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
| EP2841067A4 (en) | 2012-04-25 | 2016-04-13 | Univ California | MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME |
| JP2014001204A (ja) * | 2012-05-23 | 2014-01-09 | Kumamoto Univ | 腫瘍細胞選択的抗がん剤 |
| CN107865968B (zh) | 2012-08-03 | 2021-03-05 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗溶酶体贮积症的环糊精 |
| EP2911692B1 (en) | 2012-10-26 | 2019-08-21 | The University of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
| JP5703426B2 (ja) * | 2012-12-07 | 2015-04-22 | 国立大学法人 熊本大学 | ヒドロキシアルキル化シクロデキストリンを含む腫瘍細胞選択的抗がん剤 |
| JP6010001B2 (ja) | 2013-06-28 | 2016-10-19 | 京セラドキュメントソリューションズ株式会社 | 画像形成装置 |
| US20160151410A1 (en) | 2013-07-02 | 2016-06-02 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
| WO2015035258A1 (en) | 2013-09-06 | 2015-03-12 | The Rockefeller University | Treatment and prevention of autism and autism spectrum disorders |
| US10597696B2 (en) | 2013-09-18 | 2020-03-24 | University Of Notre Dame Du Lac | Detection of Niemann-Pick disease comprising detection of lysozyme and cathepsins |
| WO2015083736A1 (ja) | 2013-12-05 | 2015-06-11 | 国立大学法人熊本大学 | コレステロール蓄積疾患治療薬、およびそのスクリーニング方法 |
| FR3014694B1 (fr) | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
| TW201617084A (zh) * | 2014-09-25 | 2016-05-16 | 山口龍二 | 包含β－環糊精之抗腫瘤劑 |
| GB201417165D0 (en) * | 2014-09-29 | 2014-11-12 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Treatments for Autoimmune Disease |
| WO2016168772A1 (en) | 2015-04-17 | 2016-10-20 | Sens Research Foundation, Inc. | Cyclodextrin compounds for the prevention and treatment of aging |
| MX2018006247A (es) | 2015-11-19 | 2018-11-29 | Aztherapies Inc | Metodos para tratar la enfermedad de alzheimer y trastornos relacionados. |
| US20200000840A1 (en) | 2016-03-20 | 2020-01-02 | Asdera Llc | Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders |
| WO2019067145A1 (en) | 2017-08-28 | 2019-04-04 | Asdera Llc | USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DISRUPTION |
| KR20200107927A (ko) | 2017-09-28 | 2020-09-16 | 아스데라 엘엘씨 | 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도 |
-
2018
- 2018-09-18 KR KR1020207012367A patent/KR20200107927A/ko not_active Withdrawn
- 2018-09-18 EP EP18863127.9A patent/EP3687549A4/en active Pending
- 2018-09-18 WO PCT/US2018/051604 patent/WO2019067269A2/en not_active Ceased
- 2018-09-18 CA CA3076821A patent/CA3076821A1/en not_active Abandoned
- 2018-09-18 JP JP2020539678A patent/JP2020535235A/ja active Pending
- 2018-09-18 AU AU2018341235A patent/AU2018341235A1/en not_active Abandoned
- 2018-09-28 US US16/647,476 patent/US11471478B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020535235A5 (https=) | ||
| Rensen et al. | Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor | |
| CN111132700B (zh) | 双模放射性示踪剂与治疗剂 | |
| US20220133745A1 (en) | Compositions of obeticholic acid and methods of use | |
| Hochdörffer et al. | Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix | |
| Craparo et al. | Pegylated polyaspartamide–polylactide-based nanoparticles penetrating cystic fibrosis artificial mucus | |
| CN109331185B (zh) | 含有肝靶向特异性配体和甲状腺素受体激动剂的药物 | |
| JP2016540734A5 (https=) | ||
| JP2019507781A5 (https=) | ||
| CN105164143A (zh) | 用于将分子引入到乳糜微粒中的胆固醇体囊泡 | |
| JP2004509854A5 (https=) | ||
| JP2022533069A5 (https=) | ||
| JP2017514910A (ja) | 骨選択的骨形成オキシステロールビスホスホネート類似体 | |
| KR20090104830A (ko) | 중합체 결합 비스포스포네이트 흡입 제제와 이를 사용하는 방법 | |
| JP2012518012A5 (https=) | ||
| JP2012001559A (ja) | 疾患治療における脂質複合体の使用 | |
| JP2023500020A (ja) | 心血管石灰化の治療、進行の抑制、または予防における使用のためのイノシトールリン酸化合物 | |
| JP2015502946A5 (https=) | ||
| JP2017523260A5 (https=) | ||
| JP6748551B2 (ja) | コンドロイチン硫酸誘導体及び膀胱疾患処置剤 | |
| WO2000025748A1 (en) | Liposomes | |
| JP2025508985A (ja) | 特殊な分解促進メディエーター（ｓｐｅｃｉａｌｉｚｅｄ ｐｒｏｒｅｓｏｌｖｉｎｇ ｍｅｄｉａｔｏｒ）のシクロデキストリン複合体 | |
| JP2014534214A (ja) | 慢性副鼻腔炎の処置における脂質コンジュゲート | |
| Zhong et al. | Selective removal of palmitic acid from langmuir monolayers by complexation with new quaternary ammonium β-cyclodextrin derivatives | |
| JP6395880B2 (ja) | 変性病変の診断のためのリガンドとしてのフコイダン |